A Multicenter, Open-Label, Longer-Term Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study
A Multicenter, Open-Label, Longer-Term Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
This study is enrolling participants by invitation only. This is an open-label, international, longer-term extension study for eligible subjects who have participated in one of the Aimmune AR101 clinical studies.
Key Inclusion Criteria:
Key Exclusion Criteria:
Scottsdale, Arizona 85251, United States
Los Angeles, California 90027, United States
Mountain View, California 94040, United States
San Francisco, California 95148, United States
San Jose, California 95117, United States
Tampa, Florida 33613, United States
Ann Arbor, Michigan 48106, United States
New York, New York 10029, United States
Rochester, New York 14642, United States
Chapel Hill, North Carolina 27599, United States
Oklahoma City, Oklahoma 73131, United States
Strasbourg, Cedex 67091, France
Dublin, D12 V004, Ireland
Manchester, M13 9WL, United Kingdom